Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2019 | MGUS pathology

Tarek H Mouhieddine • 13 Sep 2019
IMW 2019
Multiple Myeloma Rare Diseases Smoldering Myeloma

Tarek H Mouhieddine, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the pathology and prognosis of monoclonal gammopathy of undetermined significance (MGUS) at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Tarek H Mouhieddine

Novel biomarkers for predicting disease progression in smoldering myeloma 1:41
Novel biomarkers for predicting disease progression in smoldering myeloma
Tarek H Mouhieddine • 8 Dec 2024
The current approach to risk stratification of smoldering myeloma 2:54
The current approach to risk stratification of smoldering myeloma
Tarek H Mouhieddine • 8 Dec 2024
PD-1 plus Tim-3 blockade to improve the anti-myeloma activity of T-cells of patients on talquetamab 4:43
PD-1 plus Tim-3 blockade to improve the anti-myeloma activity of T-cells of patients on talquetamab
Tarek H Mouhieddine • 8 Dec 2024
The evolution of clonal hematopoiesis and associated outcomes in multiple myeloma 5:20
The evolution of clonal hematopoiesis and associated outcomes in multiple myeloma
Tarek H Mouhieddine • 9 Dec 2023

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals